Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
About this study
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
- Condition
- Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
- Tested
- (IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
- Sponsor
- Duke University
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 12
- Minimum age: 18 years
- Study condition: Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
- (CKD Management)
- Adults with type 2 diabetes (T2D)
- Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
- Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):
- UACR \>300 mg/g or
- eGFR \<45 ml/min/1.73 m2 or
- UACR ≥30 mg/g with eGFR \<60 ml/min/1.73 m2
- Receiving \<100% GDMT at baseline.
- For patients with UACR \<30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy.
- For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).
Exclusion 6
- (CKD Management)
- Type 1 diabetes
- Most recent eGFR \<20 ml/min/1.73 m2
- Prior kidney transplant
- Autosomal dominant polycystic kidney disease (ADPKD)
- Active pregnancy or plans for conception within 1 year
Where
7 sites, 7 recruiting
University of Michigan
Ann Arbor, Michigan, United States
University of Alabama
Birmingham, Alabama, United States
Essentia Institute of Rural Health
Duluth, Minnesota, United States
Duke University
Durham, North Carolina, United States
Houston Methodist
Houston, Texas, United States
Orlando Health
St. Petersburg, Florida, United States
and 1 more site on ClinicalTrials.gov
Contact
-
Gretchen Sanders, MSN
919 6687829 gretchen.sanders@duke.edu
-
lisa monk, MSN
Potential match only. Final eligibility is determined by the study team.